Journal
CURRENT OSTEOPOROSIS REPORTS
Volume 10, Issue 1, Pages 80-85Publisher
SPRINGER
DOI: 10.1007/s11914-011-0084-x
Keywords
Calcitonin; Oral; Osteoporosis; Fracture; Osteoarthritis
Categories
Funding
- Eli Lily
- Novartis
- Amgen
Ask authors/readers for more resources
Both injectable and nasal spray calcitonins have been utilized in the treatment of postmenopausal osteoporosis for over 25 years. More widespread use of calcitonin in the treatment of osteoporosis has been hampered in part due to poor patient acceptability and compliance and the inability of patients to take this medication as an oral pill. In recent years, an oral preparation of calcitonin has been developed that combines the active peptide hormone with a caprylic acid derivative to enhance bioavailability. Clinical trials with oral calcitonin in patients with osteoarthritis are currently being conducted. A recent phase 3 study failed to demonstrate significant vertebral fracture reduction, and as a result the clinical program for oral calcitonin in osteoporosis is under review for further consideration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available